Cooper, K., Davies, Robin P., Raftery, James, Professor and Roderick, Paul. (2008) Use of a coronary heart disease simulation model to evaluate the costs and effectiveness of drugs for the prevention of heart disease. Journal of the Operational Research Society, Vol.59 (No.9). pp. 1173-1181. ISSN 0160-5682

Full text not available from this repository.

Abstract

A discrete event simulation model of the patient pathways in the treatment of coronary heart disease (CHD) was used to quantify the health gains and costs associated with increasing secondary prevention drugs prescription for patients with CHD based on the level recommended in the National Service Framework for the UK. A Gompertz distribution was sampled for time to failure ( death or non-fatal heart attack). The time to failure was modified in relation to the reduced risk of failure for those on the relevant drugs. The results from the model were validated against national data. Increasing the levels of prescription of secondary prevention drugs to those patients with CHD might prevent 100 deaths per million population per year and cost an additional 4 pound million per million population per year. With cost per life year saved of 5520 pound, this appears good value for money compared with other health technologies.

Item Type:	Journal Article
Subjects:	R Medicine > R Medicine (General) R Medicine > RC Internal medicine
Divisions:	Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	Coronary heart disease -- Mathematical models, Coronary heart disease -- Treatment -- Cost effectiveness, Coronary heart disease -- Prevention
Journal or Publication Title:	Journal of the Operational Research Society
Publisher:	Palgrave Macmillan Ltd.
ISSN:	0160-5682
Date:	September 2008
Volume:	Vol.59
Number:	No.9
Number of Pages:	9
Page Range:	pp. 1173-1181
Identification Number:	10.1057/palgrave.jors.2602468
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Restricted or Subscription Access
Funder:	National Centre for Health Outcomes Development
References:	APTT (2002). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71–86. Babad H et al (2002). The development of a simulation model of primary prevention strategies for coronary heart disease. Health Care Mngt Sci 5: 269–274. Birkhead J (2003). Where are we today? Early results from MINAP, the National Audit of Myocardial Infarction Project. Heart 89(Suppl 2): ii13–ii15. Blackburn DF et al (2005). Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol 21: 485–488. Chase D et al (2006). Using simulation to estimate the cost effectiveness of improving ambulance and thrombolysis response times after myocardial infarction. Emerg Med J 23: 67–72. Collinson J (2000). Prospective Registry of Acute Ischaemic Syndromes in the UK. 1999. Personal communication. Cooper K, Brailsford SC and Davies R (2007). Choice of modelling technique for evaluating health care interventions. J Opl Res Soc 58: 168–176. Cooper K, Brailsford SC, Davies R and Raftery J (2006). A review of health care models for coronary heart disease interventions. Health Care Mngt Sci 9: 311–324. Cooper K et al (2002). The development of a simulation model of the treatment of coronary heart disease. Health Care Mngt Sci 5: 259–267. Davies R and Davies HTO (1994). Modelling patient flows and resource provision in health systems. Omega Int J Mngt Sci 22: 123–131. Davies R et al (2003). Policy analysis for coronary heart disease: a simulation model of interventions, costs and outcomes. Final Report, Department of Health, July 2003 (www.nchod.nhs.uk— click on ‘Setting Targets’). Department of Health (1998). Hospital Episode Statistics. Personal communication. Department of Health (2000). National Service Framework: Coronary Heart Disease, Modern Standards and Service Models. The Stationery Office: London. Eren B and Primatesta P (1999). Health Survey for England: Cardiovascular Disease. Volume 1: Findings & Volume 2: Methodology and Documentation. HMSO: London. Flather MD et al (2000). Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACEInhibitor Myocardial Infarction Collaborative Group. Lancet 355: 1575–1581. Freemantle N et al (1999). Beta Blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ 318: 1730–1737. General Practice Research Database (2001). The Medicines and Healthcare products Regulatory Agency, http://www.gprd.com/ Healthcare Commission (2005). Getting to the heart of it. Coronary heart disease in England: A review of progress towards the national standards, http://www.healthcarecommission.org.uk/ Jolly K et al (1999). Randomised controlled trial of follow up care in general practice of patients with myocardial infarction and angina: Final results of the Southampton heart integrated care project (SHIP). The SHIP Collaborative Group. BMJ 318: 706–711. Lampe FC et al (2000). The natural history of prevalent ischaemic heart disease in middle-aged men. Eur Heart J 21: 1052–1062. Lawrance RA et al (2001). Use of cumulative mortality data in patients with acute myocardial infarction for early detection of variation in clinical practice: Observational study. BMJ 323: 324–327. Lerner DJ and Kannel WB (1986). Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population. Am Heart J 111: 383–390. MRC/BHF (2002). Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360: 7–22. NICE (2004). Guide to the Methods of Technology Appraisal. NICE: London. Norris RM (1998). Sudden Cardiac Death and Acute Myocardial Infarction in Three British Health Districts: The UK Heart Attack Study. British Heart Foundation: London. NWAHA (2001). North West Anglia Audit. Personal communication. Office for National Statistics (1999). Annual Abstract of Statistics. The Stationary Office: London. Office for National Statistics (2005). Annual Abstract of Statistics. The Stationary Office: London. Robinson MB (2001). EMMACE (Evaluation of Methods and Management of Acute Coronary Events). Personal communication. Sutcliffe SJ et al (2003). Incidence of coronary heart disease in a health authority in London: Review of a community register. BMJ 326: 20. Unal B, Critchley JA and Capewell S (2005). Modelling the decline in coronary heart disease deaths in England and Wales, 1981–2000: Comparing contributions from primary prevention and secondary prevention. BMJ 331: 614–619. Ward S et al (2007). A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 11(14): 1–178. Wilson DL (1994). The analysis of survival (mortality) data: Fitting Gompertz, Weibull, and logistic functions. Mech Ageing Dev 74: 15–33.
URI:	http://wrap.warwick.ac.uk/id/eprint/29418

Data sourced from Thomson Reuters' Web of Knowledge

Request changes to a record

Actions (login required)

View Item